37th International Conference on Biomedical & Cancer Research
  • Follow

Accepted Abstracts

Polypodium Leucotomos as a New Potential Antitumor Phytotherapy against Oral Cancer

Luan C Oenning1, Pammela A Lacerda1, Guilherme Cuoghi Bellato1, Lucilene Lopes-Santos1, Natalíciade Jesus  Antunes2, Bruno Augusto Linhares Almeida Mariz3, Clovis Pinto4, Tuula Salo5, Ricardo Della Coletta3, Taize MAugusto1,6, Carine Ervolinode Oliveira7, Nilva K Cervigne*1,6

1Laboratory of Molecular Biology and Cell Culture (LBMCC), Faculty of Medicine of Jundiaí (FMJ), Jundiaí, SP, Brazil.
2Laboratory of Pharmacology, University of Campinas, Campinas, SP, Brazil.
3Department of Oral Diagnosis, School of Dentistry, University of Campinas, Piracicaba, SãoPaulo, Brazil.
4Department of Morphology and Basic Pathology, Faculty of Medicine of Jundiaí (FMJ), Jundiaí, SP, Brazil.
5Department of Oral and Maxillofacial Diseases,University of Helsinki, Helsinki, Finland.
6Department of Internal Medicine, Faculty of Medicine of Jundiaí (FMJ), Jundiaí, SP, Brazil.
7Department of Pathology and Parasitology, Federal University of Alfenas, UNIFAL-MG, Alfenas, Minas Gerais, Brazil.

Citation: Oenning LC, Lacerda PA, Bellato GC, Santos LL, Antunes NJ et al (2023) Polypodium Leucotomos as a New Potential Antitumor Phytotherapy against Oral Cancer. SciTech Biomed-Cancer 2023.

Received: December 06, 2022         Accepted: December 08, 2022         Published: December 08, 2022

Abstract

Oral cancer refer stomalignant tumors, of which 90% are squamous cell carcinomas (OSCC). These malignancies exhibit rapid progression, poor prognosis, and often mutilating therapeutical approaches. The determination of a prophylactic and/or therapeutic antitumor role of Polypodium leucotomos (PL) would be relevant in developing new tools for prevention and treatment. We aimed to determine the antitumor effect of PL by treating OSCC cell lines with PL metabolites and evaluating its action during OSCC progression in vivo. PL treatment successfully impaired cell cycling andproliferation, migration, and invasion, enhanced apoptosis, and modulated macrophagepolarization associated with the OSCC tumoral immune-inflammatory response. PL significantly decreased the expression of MMP1(p<0.01) and MMP2(p<0.001),and increased the expression of TIMP1(p<0.001) and TIMP2(p<0.0001) in these cells. The mesenchymal-epithelium transition phenotype was promoted in cells treated with PL, through up regulation of E-CAD (p<0.001) and reduction of N-CAD (p<0.05). PL restrained OSCC progression in vivo by inhibiting tumor volume growth and decreasing the number of severe dysplasia lesions and squamous cell carcinomas. Ki-67 was significantly higher expressed in tonguet issues not treated with PL (p<0.05),and anotable reduction in Bcl2 (p<0.05) and Pcna (p<0.05) cell proliferation-associated genes was found in dysplastic lesions and OSCCs of PL-treated mice. Finally, N-cad (Cdh2), Vim, and Twist were significantly reduced in tongue tissues treated with PL. In conclusion, PL significantly decreased OSCC carcinogenic processes in vitro and inhibit edtum or progression in vivo. Altogether, these results suggest that PL plays an important antitumor role in processes associated with oral carcinogenesis and may be a potential phytotherapeutic target for the prevention and/or adjuvant treatment of OSCCs.
Keywords: Polypodium leucotomos, Polyphenolic extract, Antitumor effect, Immune-inflammation, EMT, OSCC progression